Clinical Trial

Study of SIR2501 in Solid Tumor Patients Receiving Paclitaxel

Name: Study of SIR2501 in Solid Tumor Patients Receiving Paclitaxel — clinical trial record (NCT07765446)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Not Yet Recruiting Phase 2

View on ClinicalTrials.gov →

Summary

This Phase 2, open-label study will evaluate the safety, tolerability, and pharmacokinetics of SIR2501 in adults with solid tumors who are scheduled to receive paclitaxel-based chemotherapy. The study will also explore whether SIR2501 has the potential to reduce the development of chemotherapy-induced peripheral neuropathy (CIPN).

Trial Details

NCT Number	NCT07765446
Lead Sponsor	Sironax USA, Inc.
Conditions	Chemotherapy-induced Peripheral Neuropathy
Enrollment	18 participants
Start Date	2026-08-03
Primary Completion	2027-12-31 (estimated)
Study Completion	2027-12-31 (estimated)
Updated on ClinicalTrials.gov	2026-08-14